Extended Data Fig. 2: Anticancer activity of HDAC6 inhibitors. | Nature Cancer

Extended Data Fig. 2: Anticancer activity of HDAC6 inhibitors.

From: Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer

Extended Data Fig. 2: Anticancer activity of HDAC6 inhibitors.The alternative text for this image may have been generated using AI.

(a) The western blot shows the titration of ricolinostat to identify an effective dose (accumulation of Ac-α-Tubulin) without off-target effects in class-I HDACs (accumulation of Ac-H3K27). SAHA is used as a control Pan-HDAC inhibitor. WT-blot results were reproduced n = 3 times from independent experiments. (b) Chemical structure of the different HDAC6 inhibitors used in Fig. 1e. (c) Normalized cell number 6 days after transfection with individualized siRNAs targeting HDAC6 or non-targeting control (NTC) (n = 3 independent independent experiments per siRNA). The WT-blots show the silencing efficiency. WT-blot results were reproduced n = 3 times from independent experiments. All error bars represent Mean±SD. P value was estimated by two-tailed t test. (d) The graphic shows the lack of synergistic activity between ricolinostat and commonly used chemotherapy (paclitaxel and doxorubicin) in MDA-MB-436 cells. In contrast, cells sensitive to ricolinostat MDA-MB-453, SK-BR-3 and MDA-MB-474 show synergistic activity between ricolinostat and chemotherapy. R and S indicate ricolinostat resistance and sensitivity respectively. N = 3 independent replicate experiments per drug combination and concentration. (e) Histological intratumoral evaluation of H&E, Caspase-3, and Ki-67 in tumor samples from Fig. 1b. Quantification is also shown in bar graphs. Notice that the combo treatment (Pac+Ric) is not shown because all tumors regressed with this treatment. The white asterisks indicate necrotic areas and the white arrows indicate Caspase-3 positive stained cells. All error bars represent Mean±SD. P value was estimated by two-tailed t test. N = 6 samples from individual tumors. (f) The list shows all the transgenic mouse models evaluated by the HDAC6 score in Fig. 2c, d and indicates their correlation with human BCs. (g) Kaplan–Meier graphic showing the survival of the MMTV tumors in Fig. 2e. Control n = 7; ricolinostat (Ric) n = 8; paclitaxel (Pac) n = 8; Ric+Pac n = 8. P value was estimated using two-tailed Log-Rank test.

Source data

Back to article page